查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179900

2023-2030 年全球电气诊断设备市场

Global Electro-Diagnostic Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

电诊断是一种测试技术，可以估计体内电活动的速率和范围。 电诊断仪器检查肌肉和神经衝动的电传导和活动。 这些设备可帮助从业者和医生为患有肌病、神经病、神经肌肉接头疾病、神经丛病等的患者推荐诊断。 常见的电学诊断包括神经传导研究 (NCS)、体感诱发电位研究 (SSEP) 和肌电图 (EMG)。

市场动态

在预测期内，产品推出的增加、老年人口的增加以及相关的慢性病正在推动全球电诊断设备市场的增长。

不断增加的产品介绍正在推动市场的增长。

在预测期内，不断增长的市场发展、不断增加的老年人口和慢性病正在推动全球电诊断设备市场的增长。 例如 2020 年 9 月，美国 FDA 批准的个人心电图 (ECG) 技术公司 AliveCor 今天推出了经过临床验证的个人心电图设备 KardiaMobile 6L。以全球唯一的 6 进入印度市场-铅，FDA 批准的个人 ECG 设备能够检测 3 种最常见的心律失常类型，心房颤动 (AFib)、心动过缓和心动过速。 由于这些疾病需要定期监测，因此患者可以在家中自行检测这些心律失常。 KardiaMobile 6L 可以在短短 30 秒内记录医疗心电图。 此外，2022 年 10 月，印度第一家非接触式远程患者监护 (RPM) 公司 Dozee 将宣布推出门诊心电图 (ECG) 贴片，以监测心血管疾病 (CVD) 患者的情况。

此外，2020 年 7 月，提供神经病学、AI 和机器学习等脑相关产品和解决方案的医疗设备和技术公司 Brain Scientific 推出了一款名为“Neuro Cap”的一次性脑电耳机，该耳机经过改进和添加了新功能。 同样，2022年1月，Cadwell在美国推出了“阴部（骨盆底）刺激记录电极和电缆”。 Spethmedica 製造的阴蒂电极与 Sierra Summit 系统一起开发，用于评估肛门括约肌的阴蒂神经末梢潜伏期 (PNTML)。 因此，上述数据表明，在预测期内，增加产品引进将提振全球电气诊断设备市场。

设备的高成本预计会阻碍全球电气诊断设备市场的增长。

然而，阻碍市场增长的关键因素之一是安装和维护电气诊断设备的高成本。 例如，手持式心电图机的价格为 500 美元，笔记本电脑式心电图机的价格约为 1000-2000 美元。 同时，动态心电图设备的平均成本为 1000 到 3000 美元。

COVID-19 的影响。

COVID-19 大流行对全球电气诊断设备市场产生了一定程度的影响。 在大流行初期，由于对 COVID-19 的高度关注，大多数诊断程序被取消或推迟。 然而，随着 COVID-19 病例的减少，电诊断程序已成为一种更加谨慎的做法。 例如，2020 年初，美国确认停止选择性医疗程序，包括非紧急门诊和住院电诊断 (EDx) 测试。 此后，EDx 实验室在美国神经肌肉和电诊断医学学会 (AANEM) 的指导下重新开放，儘管某些地区每天的新病例数有所下降。 此外，COVID-19 还带动了个人监控设备的发展，对市场产生了积极影响。 因此，可以说，COVID-19对全球电诊断设备市场产生了多方面的影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 增加产品发布
      • 慢性病增加
    • 约束因素
      • 设备成本高
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 心电图 (ECG)
  • 肌电图 (EMG)
  • 脑电图 (EEG)
  • 神经传导研究 (NCS)
  • 视网膜电图 (ERG)
  • 胃电图 (EGG)

第 8 章产品流动性

  • 固定式
  • 便携式

第 9 章最终用户

  • 医院和诊所
  • 门诊手术中心 (ASC)
  • 家庭护理
  • 诊断中心

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第12章公司简介

  • GE Healthcare
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Medtronic
  • Abbott
  • Boston Scientific
  • Bionet America, Inc.
  • Philips Healthcare
  • Cardinal Health
  • B. Braun Melsungen AG
  • Stryker Corporation
  • Becton, Dickinson and Company

第13章数据M

简介目录
Product Code: DMMD6130

Market Overview

The global electro-diagnostic devices market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Electro-diagnostics is a testing technique that estimates the body's speed or extent of electrical activity. Electro-diagnostics equipment examines muscle and nerve impulses' electrical conduction or activity. These devices help practitioners or physicians recommend diagnoses for patients such as myopathy, neuropathy, neuromuscular junction disorder, and plexopathy. The major electro-diagnostic study includes nerve conduction studies (NCS), somatosensory evoked potential studies (SSEPs), and electromyography (EMG).

Market Dynamics

The rising product introductions, growing geriatric population and associated chronic diseases are boosting the global electro-diagnostic devices market growth in the forecast period.

The increasing product launches are fueling growth in the market.

The increased market developments, growing geriatric population and chronic diseases are boosting the global Electro-Diagnostic Devices market growth in the forecast period. For instance, in September 2020, AliveCor, a US FDA-approved personal electrocardiogram (ECG) technology firm, today entered the Indian market with the introduction of its clinically-validated personal ECG device, KardiaMobile 6L, the world's only six-lead, FDA-cleared personal ECG device and can detect three most common arrhythmias, the atrial fibrillation (AFib), bradycardia, and tachycardia. Since these conditions require regular monitoring, the patients can test themselves for these arrhythmias at home. The KardiaMobile 6L can record a medical-grade ECG in only 30 seconds. Also, in October 2022, Dozee, India's first contactless remote patient monitoring (RPM) company, declared about launching an ambulatory electrocardiogram (ECG) patch to monitor cardiovascular disease (CVD) patients.

Moreover, in July 2020, Brain Scientific Inc., a medical device and technology company delivering products and solutions associated with the brain, including neurology, AI and machine learning, improved its disposable EEG headset, NeuroCap, with new features. Likewise, in January 2022, Cadwell launched the Pudendal (Pelvic Floor) Stimulating and Recording Electrode and Cable in the United States. The pudendal electrode, fabricated by Spes Medica, is developed with the Sierra Summit system to assess pudendal nerve terminal motor latency (PNTML) in the anal sphincter. Therefore, the data above indicates that the increased product introductions boost the global electro-diagnostic devices market during the forecasted period.

The high cost of the equipment is expected to hamper global electro-diagnostic devices market growth.

However, one of the important factors hampering the market growth is the high setup and upkeep costs of electro-diagnostic devices. For instance, handheld ECG machines can be $500, and laptop-based ECG machines cost about $1000-$2,000. At the same time, portable ECG machines cost between $1,000-$3,000 on average.

COVID-19 Impact.

The COVID-19 pandemic moderately impacted the global electro-diagnostic devices market. Most diagnostics procedures were canceled or postponed during the early pandemic day since the major focus was on COVID-19. Still, later with the decrease in cases of COVID-19, electro-diagnosis procedures were performed with extreme precautions. For instance, in early 2020, the cancellation of elective medical procedures in the United States, including non-urgent outpatient and inpatient electro-diagnostic (EDx) studies, was observed. While certain regions subsequently showed a decrease in daily new cases, EDx laboratories were reopened under the direction of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Furthermore, COVID-19 led to the development of personalized monitoring devices which positively impacted the market. Therefore, from the data mentioned, COVID-19 had a mixed impact on the global electro-diagnostic devices market.

Segment Analysis

Electrocardiography (ECG) devices are expected to dominate the electro-diagnostic devices market throughout the forecast period (2022-2029).

Electrocardiography (ECG) product is estimated to hold most of the market share throughout the forecast period. The growing cases of cardiovascular diseases worldwide ensure that the electrocardiography (ECG) devices segment grows at a high CAGR during the forecast period. For instance, according to the WHO, cardiovascular diseases (CVDs) are the major cause of death globally, taking over 17.9 million lives annually. Over 75% of CVD-related deaths happen in low- and middle-income countries. The World Heart Federation forecasts over 23 million CVD-related deaths annually by 2030.

Furthermore, the increased initiatives by various entities to spread awareness about cardiac health are boosting segment growth in the forecasted period. For example, NHLBI, The Heart Truth, and organizations around the United States on National Wear Red Day marked each year on the first Friday in February to obtain greater awareness of heart disease as a leading cause of death for Americans. Also, on February 10, 2019, the Heart Foundation introduced the coordinated advertising and editorial 'Serial Killer' campaign in collaboration with News Corp Australia to point out to Australians that heart disease is the nation's leading cause of death. The campaign delivered Australians with an easy-to-use online tool, the Heart Age Calculator, to enable them to evaluate their own risk for heart disease and called on the Government to support the prevention of heart disease by supplying a Medicare advantage for Heart Health Checks.

Additionally, CDC run Million Hearts is a national endeavor to avert 1 million heart attacks and strokes in the period of five years. It concentrates on enforcing a small set of evidence-based preferences and targets that can enhance cardiovascular health for all. Therefore, from the mentioned data, it is estimated that the electrocardiography (ECG) devices segment will grow at a high CAGR throughout the forecast period.

Geographical Analysis

North America holds the largest market share of global electro-diagnostic devices.

North America is anticipated to hold most of the global electro-diagnostic devices market during the forecasted period (2022-2029) because of the increasing number of developed and well-staffed hospitals and increased healthcare expenditure in this region. For instance, according to the American Hospital Association, currently, over 6,093 hospitals have more than 920,531 staff bed capacity, which in 2022 had over 33,356,853 admissions generating $ 1,213,881,001,000 of expenditure. In addition, the growing geriatric population and related chronic disease cases in this region contribute to the region's dominance over the global electro-diagnostic device market. For example, according to the United States Census Bureau, over 54 million adults ages 65 and older living in the United States in 2021, accounting for around 16.5% of the nation's population. The number of older U.S. adults is growing. By 2050, the total number of adults ages 65 and older is projected to reach 85.7 million, making up around 20% of the overall U.S. population.

Furthermore, according to the CDC, six out of ten U.S. adults have at least one chronic disease. Moreover, according to the same source, approximately 697,000 people in the United States died from heart disease in 2020. The American Heart Association estimated that By 2035 over 130 million U.S. adults will have some heart disease. Thus, the mentioned data indicates that North America will dominate the global electro-diagnostic devices market in the forecast period.

Competitive Landscape

The global electro-diagnostic devices market is fairly consolidated, with selected key players accounting for the predominant market share. The major players with significant market share include Stryker Corporation, Becton, Dickinson and Company, Boston Scientific, Medtronic, Abbot, Bionet America, Inc., Philips Healthcare, Cardinal Health, GE Healthcare, and B. Braun Melsungen AG, among others. The key players focus on R&D, product innovation, and product outreach through distribution through local suppliers and distributors worldwide. For instance, in November 2022, Bionet America, Inc. announced its plan to restructure its diagnostics division to make around 300 million euros in savings by 2025.

GE Healthcare

Overview:

GE Healthcare is headquartered in Chicago, Illinois, United States, and was founded in 2004. It is a subsidiary of the American Multinational Conglomerate General Electric. It is a leading manufacturer and distributor of diagnostic imaging and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

GE Healthcare's product portfolio of electro-diagnostic devices has CARESCAPE B450 Monitor: The CARESCAPE B450 monitor functions seamlessly with the CARESCAPE ONE monitor or CARESCAPE Patient Data Module (PDM) and one additional e-module, delivering the ability to monitor patients with various insights. Portable and inexpensive, it's developed with emergency departments, surgery centers, and step-down units in mind.

The global electro-diagnostic devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches
      • 4.1.1.2. Growing Prevalence of Chronic Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Electrocardiography (ECG)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Electromyogram (EMG)
  • 7.4. Electroencephalography (EEG)
  • 7.5. Nerve Conduction (NCS)
  • 7.6. Electroretinography (ERG)
  • 7.7. Electrogastrography (EGG)

8. By Product Mobility

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 8.1.2. Market Attractiveness Index, By Product Mobility
  • 8.2. Stationary
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Portable

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Homecare
  • 9.5. Diagnostic Centers

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Mobility
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. GE Healthcare
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medtronic
  • 12.3. Abbott
  • 12.4. Boston Scientific
  • 12.5. Bionet America, Inc.
  • 12.6. Philips Healthcare
  • 12.7. Cardinal Health
  • 12.8. B. Braun Melsungen AG
  • 12.9. Stryker Corporation
  • 12.10. Becton, Dickinson and Company

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us